We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy. This evidence concerns the gene FCGR3B and post-transplant lymphoproliferative disease.